This company has been marked as potentially delisted and may not be actively trading. Conatus Pharmaceuticals (CNAT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CNAT vs. XBIO, KZIA, ALLR, LIXT, JAGX, EVOK, PPBT, KTTA, CNSP, and GLTOShould you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include Xenetic Biosciences (XBIO), Kazia Therapeutics (KZIA), Allarity Therapeutics (ALLR), Lixte Biotechnology (LIXT), Jaguar Health (JAGX), Evoke Pharma (EVOK), Purple Biotech (PPBT), Pasithea Therapeutics (KTTA), CNS Pharmaceuticals (CNSP), and Galecto (GLTO). These companies are all part of the "medical" sector. Conatus Pharmaceuticals vs. Xenetic Biosciences Kazia Therapeutics Allarity Therapeutics Lixte Biotechnology Jaguar Health Evoke Pharma Purple Biotech Pasithea Therapeutics CNS Pharmaceuticals Galecto Conatus Pharmaceuticals (NASDAQ:CNAT) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation. Which has more risk and volatility, CNAT or XBIO? Conatus Pharmaceuticals has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.3, meaning that its stock price is 130% more volatile than the S&P 500. Do analysts rate CNAT or XBIO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conatus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Xenetic Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community prefer CNAT or XBIO? Conatus Pharmaceuticals received 363 more outperform votes than Xenetic Biosciences when rated by MarketBeat users. Likewise, 79.67% of users gave Conatus Pharmaceuticals an outperform vote while only 66.92% of users gave Xenetic Biosciences an outperform vote. CompanyUnderperformOutperformConatus PharmaceuticalsOutperform Votes53779.67% Underperform Votes13720.33% Xenetic BiosciencesOutperform Votes17466.92% Underperform Votes8633.08% Do institutionals & insiders hold more shares of CNAT or XBIO? 15.2% of Conatus Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 11.3% of Conatus Pharmaceuticals shares are owned by company insiders. Comparatively, 14.7% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, CNAT or XBIO? Xenetic Biosciences has lower revenue, but higher earnings than Conatus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConatus Pharmaceuticals$21.72M0.04-$11.39MN/AN/AXenetic Biosciences$2.50M1.47-$4.14M-$2.57-0.93 Does the media refer more to CNAT or XBIO? In the previous week, Xenetic Biosciences had 2 more articles in the media than Conatus Pharmaceuticals. MarketBeat recorded 2 mentions for Xenetic Biosciences and 0 mentions for Conatus Pharmaceuticals. Xenetic Biosciences' average media sentiment score of 0.33 beat Conatus Pharmaceuticals' score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Conatus Pharmaceuticals Neutral Xenetic Biosciences Neutral Is CNAT or XBIO more profitable? Conatus Pharmaceuticals has a net margin of -52.42% compared to Xenetic Biosciences' net margin of -161.63%. Conatus Pharmaceuticals' return on equity of -48.22% beat Xenetic Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Conatus Pharmaceuticals-52.42% -48.22% -39.32% Xenetic Biosciences -161.63%-49.51%-43.99% SummaryConatus Pharmaceuticals beats Xenetic Biosciences on 8 of the 15 factors compared between the two stocks. Get Conatus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNAT vs. The Competition Export to ExcelMetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$962,000.00$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.29%P/E Ratio-0.106.9521.9417.82Price / Sales0.04231.03380.9597.68Price / CashN/A65.6738.2634.64Price / Book0.055.936.453.98Net Income-$11.39M$143.22M$3.22B$247.81M Conatus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNATConatus PharmaceuticalsN/A$0.03flatN/A-94.2%$962,000.00$21.72M-0.1030XBIOXenetic Biosciences1.3947 of 5 stars$2.32+0.9%N/A-40.4%$3.58M$2.50M-0.874Short Interest ↓KZIAKazia Therapeutics3.3191 of 5 stars$0.71flat$11.50+1,519.7%-4.7%$3.58M$2.31M0.0012Short Interest ↓Gap DownALLRAllarity Therapeutics0.2349 of 5 stars$0.80+0.4%N/A-98.0%$3.56MN/A0.0010Short Interest ↑LIXTLixte Biotechnology0.9429 of 5 stars$1.25+13.6%N/A-64.8%$3.36MN/A-0.724Short Interest ↓Gap UpJAGXJaguar Health0.0665 of 5 stars$4.93+2.8%N/A-97.9%$3.32M$11.69M0.0050Short Interest ↑Gap UpEVOKEvoke Pharma0.198 of 5 stars$2.22-5.5%N/A-62.6%$3.31M$10.25M-0.204Short Interest ↑PPBTPurple Biotech1.5611 of 5 stars$2.47-1.0%$33.00+1,238.7%N/A$3.28MN/A-0.2820News CoverageKTTAPasithea Therapeutics0.4425 of 5 stars$1.21-0.4%N/A-80.6%$3.26MN/A-0.093Short Interest ↑CNSPCNS Pharmaceuticals1.1506 of 5 stars$1.10-1.8%$25.00+2,172.7%-99.8%$3.19MN/A-0.015Short Interest ↑GLTOGalecto2.2704 of 5 stars$2.38-6.9%$10.00+321.1%-86.5%$3.15MN/A-0.1240Short Interest ↑News Coverage Related Companies and Tools Related Companies Xenetic Biosciences Competitors Kazia Therapeutics Competitors Allarity Therapeutics Competitors Lixte Biotechnology Competitors Jaguar Health Competitors Evoke Pharma Competitors Purple Biotech Competitors Pasithea Therapeutics Competitors CNS Pharmaceuticals Competitors Galecto Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNAT) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Conatus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNAT Stock Free CNAT Stock Alerts